Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of tapentadol immediate-release (IR [CG5503]) for use in the relief of moderate to severe acute pain, compared with placebo, in adult Taiwanese patients with acute pain following bunionectomy.


Clinical Trial Description

Patients undergoing bunionectomy (a surgical procedure to remove a bunion, an enlargement of the joint at the base of the big toe comprised of bone and soft tissue) often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid analgesics. Tapentadol (CG5503) is a newly synthesized opioid drug acting as a centrally acting analgesic like opioid analgesics but has a different mode of action. This study, a randomized (patients are assigned different treatments based on chance), double-blind (neither investigator nor patient knows which treatment the patient receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), parallel-group (each group of patients will be treated at the same time), multicenter study (the study is performed at more than one clinic) is designed to evaluate the effectiveness (level of pain control) and safety (side effects) of tapentadol immediate-release (IR) 50 mg or 75 mg versus placebo. The study will consist of a screening phase, during which the patients will be evaluated for study entry (Days -28 to -2) followed by the surgical period (Day -1) during which the bunionectomy will be performed and which will start with the first surgical incision and continues until termination of the popliteal sciatic block (PSB) infusion. During the qualification period (Day 1) which starts after termination of the post-operative continuous PSB infusion, patients will be evaluated for entry in the double blind treatment phase. Patients will be randomly assigned to one of three treatment groups to receive either 50 mg tapentadol IR, 75 mg tapentadol IR or a placebo if their PI is equal to or greater than 4 on a 0-10 numerical rating scale. The inpatient double-blind treatment period will be 72 hours in duration and will include a final end-of-double-blind evaluation (on Day 4, i.e., 72 hours after the administration of the first dose) for all patients. Any patient requiring analgesia for pain relief in addition to study drug during the double-blind treatment period will be discontinued from the study due to lack of efficacy. All patients who discontinue for lack of efficacy will complete pain assessments and the Patient Global Impression of Change (PGIC) before receiving rescue medication. Pain intensity and pain relief will be periodically assessed during the treatment period using rating scales. Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. The study length, including the screening period, will be up to a maximum duration of 32 days. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01813890
Study type Interventional
Source Janssen-Cilag International NV
Contact
Status Completed
Phase Phase 3
Start date January 2013
Completion date January 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04473196 - The Effect of Weight Bearing on Patient Outcomes Following 1st MTP Joint Fusion N/A
Recruiting NCT05587569 - Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D) N/A
Recruiting NCT05555459 - Performance and Safety Evaluation of Inion CompressOn Screw in Foot and Ankle Surgeries. PMCF Investigation N/A
Completed NCT02121119 - Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump Phase 4
Enrolling by invitation NCT00600899 - Home Infusors for Analgesia After Foot Surgery Phase 4
Completed NCT05579054 - Translation, Validity, and Reliability of the Foot Posture Index (FPI-6) - Turkish Version
Terminated NCT05082012 - Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D) N/A
Recruiting NCT05051709 - Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus N/A
Recruiting NCT04716140 - Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions in Hallux Valgus Surgery N/A
Active, not recruiting NCT04145882 - Efficacy of Additional Osteotomies to Correct Hallux Valgus N/A
Completed NCT04468555 - Hallux Valgus Manual Therapy Based on Global Postural Reeducation. N/A
Terminated NCT03257540 - Early Weight-Bearing After Lapidus Arthrodesis
Completed NCT03846687 - Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
Completed NCT04365712 - Osteotomy of the 1st Metatarsal for Hallux Valgus Using Pneumatic Oscillating Saw or Piezoelectric Scalpel N/A
Recruiting NCT02282956 - Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery Phase 4
Withdrawn NCT01555216 - Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block N/A
Completed NCT00683137 - Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery Phase 3
Terminated NCT04103814 - Effect of Topical CBD Cream for Degenerative Hallux Disorders Phase 2/Phase 3
Completed NCT03423498 - The Toe-spread-out Exercise in Patients With Hallux Valgus and Without the Deformity N/A
Not yet recruiting NCT06076655 - Hallux Valgus Treatment Developed for Children With Cerebral Palsy N/A